Synageva BioPharma Corporation, previously known as AviGenics, is a clinical stage biopharmaceutical company acquired in 2015 by Alexion - itself having been SBIR Involved some years earlier. Following the acquisition, the company merged with Alexion to continue to develop treatments for patients with rare diseases such as lysosomal acid lipase (LAL) deficiency, which causes a build-up of fatty materials in the liver, gut, organs or blood vessel walls. The firm's lead program, SBC-102, is a recombinant human lysosomal acid lipase currently under clinical investigation for the treatment of patients with early onset and late onset lysosomal acid lipase (LAL) deficiency. In 2011, shortly after raising $25mm in a late-stage financing along with several other prior rounds, the then private Synageva BioPharma merged with public firm Trimeris Inc. (therapies for viral diseases) in a stock swap. Following the transaction, Synageva and Trimeris own 75% and 25% of the company, respectively have issued multiple FOPOs.
